467 related articles for article (PubMed ID: 28244067)
41. Targeting Oncogenic WNT Signalling with WNT Signalling-Derived Peptides.
Yadav V; Jobe N; Mehdawi L; Andersson T
Handb Exp Pharmacol; 2021; 269():279-303. PubMed ID: 34455485
[TBL] [Abstract][Full Text] [Related]
42. Small-molecule inhibitors of Wnt signaling pathway: towards novel anticancer therapeutics.
Zheng S; Liu J; Wu Y; Huang TL; Wang G
Future Med Chem; 2015; 7(18):2485-505. PubMed ID: 26670195
[TBL] [Abstract][Full Text] [Related]
43. Targeting inflammation to reduce cardiovascular disease risk.
Maffia P; Cirino G
Br J Pharmacol; 2017 Nov; 174(22):3895-3897. PubMed ID: 29080212
[TBL] [Abstract][Full Text] [Related]
44. Wnt Signaling and Drug Resistance in Cancer.
Zhong Z; Virshup DM
Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618
[TBL] [Abstract][Full Text] [Related]
45. The Wnt pathway: emerging anticancer strategies.
Gupta A; Verma A; Mishra AK; Wadhwa G; Sharma SK; Jain CK
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):138-47. PubMed ID: 23432158
[TBL] [Abstract][Full Text] [Related]
46. Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs.
Madan B; Virshup DM
Mol Cancer Ther; 2015 May; 14(5):1087-94. PubMed ID: 25901018
[TBL] [Abstract][Full Text] [Related]
47. Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine.
Lum L; Chen C
Curr Med Chem; 2015; 22(35):4091-103. PubMed ID: 26310918
[TBL] [Abstract][Full Text] [Related]
48. Targeting the wingless signaling pathway with natural compounds as chemopreventive or chemotherapeutic agents.
Teiten MH; Gaascht F; Dicato M; Diederich M
Curr Pharm Biotechnol; 2012 Jan; 13(1):245-54. PubMed ID: 21466435
[TBL] [Abstract][Full Text] [Related]
49. Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells.
Wachter J; Neureiter D; Alinger B; Pichler M; Fuereder J; Oberdanner C; Di Fazio P; Ocker M; Berr F; Kiesslich T
Int J Biol Sci; 2012; 8(1):15-29. PubMed ID: 22211101
[TBL] [Abstract][Full Text] [Related]
50. Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway.
Amado NG; Predes D; Fonseca BF; Cerqueira DM; Reis AH; Dudenhoeffer AC; Borges HL; Mendes FA; Abreu JG
J Biol Chem; 2014 Dec; 289(51):35456-67. PubMed ID: 25359775
[TBL] [Abstract][Full Text] [Related]
51. Carotenoids: biochemistry, pharmacology and treatment.
Milani A; Basirnejad M; Shahbazi S; Bolhassani A
Br J Pharmacol; 2017 Jun; 174(11):1290-1324. PubMed ID: 27638711
[TBL] [Abstract][Full Text] [Related]
52. Notch and Wnt signaling pathway in cancer: Crucial role and potential therapeutic targets (Review).
Xiao YF; Yong X; Tang B; Qin Y; Zhang JW; Zhang D; Xie R; Yang SM
Int J Oncol; 2016 Feb; 48(2):437-49. PubMed ID: 26648421
[TBL] [Abstract][Full Text] [Related]
53. Targeting the Wnt/β-catenin signaling pathway in human cancers.
Yao H; Ashihara E; Maekawa T
Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
[TBL] [Abstract][Full Text] [Related]
54. Perspectives on the role of Wnt biology in cancer.
Mirabelli CK; Nusse R; Tuveson DA; Williams BO
Sci Signal; 2019 Jul; 12(589):. PubMed ID: 31289213
[TBL] [Abstract][Full Text] [Related]
55. WNT Signalling in Osteoarthritis and Its Pharmacological Targeting.
De Palma A; Nalesso G
Handb Exp Pharmacol; 2021; 269():337-356. PubMed ID: 34510305
[TBL] [Abstract][Full Text] [Related]
56. The involvement of noncanonical Wnt signaling in cancers.
Chen Y; Chen Z; Tang Y; Xiao Q
Biomed Pharmacother; 2021 Jan; 133():110946. PubMed ID: 33212376
[TBL] [Abstract][Full Text] [Related]
57. Discovery of small molecule inhibitors of the Wnt/β-catenin signaling pathway by targeting β-catenin/Tcf4 interactions.
Yan M; Li G; An J
Exp Biol Med (Maywood); 2017 Jun; 242(11):1185-1197. PubMed ID: 28474989
[TBL] [Abstract][Full Text] [Related]
58. Advances in targeting the WNT/β-catenin signaling pathway in cancer.
Chatterjee A; Paul S; Bisht B; Bhattacharya S; Sivasubramaniam S; Paul MK
Drug Discov Today; 2022 Jan; 27(1):82-101. PubMed ID: 34252612
[TBL] [Abstract][Full Text] [Related]
59. Understanding the regulation of β-catenin expression and activity in colorectal cancer carcinogenesis: beyond destruction complex.
Taank Y; Agnihotri N
Clin Transl Oncol; 2021 Dec; 23(12):2448-2459. PubMed ID: 34426910
[TBL] [Abstract][Full Text] [Related]
60. Atypical regulators of Wnt/β-catenin signaling as potential therapeutic targets in Hepatocellular Carcinoma.
Chen J; Rajasekaran M; Hui KM
Exp Biol Med (Maywood); 2017 Jun; 242(11):1142-1149. PubMed ID: 28429652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
